Atazanavir for HIV Infected Individuals: An Early Access Program
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00046345 |
Recruitment Status
:
No longer available
First Posted
: September 30, 2002
Last Update Posted
: April 14, 2011
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
HIV Infections | Drug: Atazanavir (BMS-232632) |
Study Type : | Expanded Access |
Study Start Date : | May 2002 |
Study Completion Date : | July 2003 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key inclusion criteria:
- Patients eligible for inclusion into the EAP are those that are a virologic failure due to resistance, intolerance and/or adherence problems with current anti-HIV medications;
- OR have multiple toxicities or intolerance to their anti-HIV medication but are not a virologic failure;
- OR have severe elevated lipids in the blood (e.g., cholesterol, triglycerides) that do not respond to lipid-lowering medication.
Key exclusion Criteria:
- Restrictions apply regarding the use of atazanavir with specific medications which may have a potential to cause possible side effects when taken together.
- Patients will also be excluded for any of the following reasons: 1) pregnancy or breast feeding, 2) elevated liver enzymes, 3) significant cardiovascular disease, or 4) other restrictions as indicated in the protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00046345

Additional Information:
ClinicalTrials.gov Identifier: | NCT00046345 History of Changes |
Other Study ID Numbers: |
AI424-900 |
First Posted: | September 30, 2002 Key Record Dates |
Last Update Posted: | April 14, 2011 |
Last Verified: | April 2011 |
Keywords provided by Bristol-Myers Squibb:
treatment experienced |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |
Atazanavir Sulfate HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |